Drug intelligence / Profile preview

CSP-9222

Development stage: Unknown
Lead developer: Sonus Pharmaceuticals
Modality: Small Molecules

Overview

CSP-9222 is a small molecule drug in preclinical development by OncoGenex Pharmaceuticals. It is designed as a caspase stimulant, which means it stimulates caspase enzymes, key mediators of apoptosis (programmed cell death), and may therefore act by promoting apoptosis in cancer cells. CSP-9222 has been investigated primarily in the context of solid tumors and is part of OncoGenex's pipeline of oncology drug candidates[7][1][6]. No clinical trial results or advanced clinical development stages for CSP-9222 have been reported.

Targets

CASP (Caspase family)

Beyond the preview

Go deeper on CSP-9222.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSP-9222.

Explore the full profile